RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS

BACKGROUND: TRK fusions are oncogenic drivers of a variety of tumors, many of which can involve the central nervous system (CNS). Larotrectinib is a selective TRK inhibitor FDA-approved for the treatment of TRK fusion cancers (Drilon et al., NEJM 2018). Here we report on the clinical activity of lar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Doz, Francois, Geoerger, Birgit, DuBois, Steven G, Grilley-Olson, Juneko E, van Tilburg, Cornelis M, Italiano, Antoine, Lissat, Andrej, Jin Kang, Hyoung, Tahara, Makoto, Boni, Valentina, Perreault, Sebastien, Capra, Michael, Nanda, Shivani, Brega, Nicoletta, Holynskyj, Ariadna, Ziegler, David S, Hong, David S, Hyman, David M, Drilon, Alexander
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Rare Tumors
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847856/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.968
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados